JP2024519917A5 - - Google Patents

Info

Publication number
JP2024519917A5
JP2024519917A5 JP2023571950A JP2023571950A JP2024519917A5 JP 2024519917 A5 JP2024519917 A5 JP 2024519917A5 JP 2023571950 A JP2023571950 A JP 2023571950A JP 2023571950 A JP2023571950 A JP 2023571950A JP 2024519917 A5 JP2024519917 A5 JP 2024519917A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
subject
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030111 external-priority patent/WO2022246114A2/en
Publication of JP2024519917A publication Critical patent/JP2024519917A/ja
Publication of JP2024519917A5 publication Critical patent/JP2024519917A5/ja
Pending legal-status Critical Current

Links

JP2023571950A 2021-05-20 2022-05-19 リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用 Pending JP2024519917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191142P 2021-05-20 2021-05-20
US63/191,142 2021-05-20
PCT/US2022/030111 WO2022246114A2 (en) 2021-05-20 2022-05-19 Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof

Publications (2)

Publication Number Publication Date
JP2024519917A JP2024519917A (ja) 2024-05-21
JP2024519917A5 true JP2024519917A5 (https=) 2025-05-23

Family

ID=84083636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571950A Pending JP2024519917A (ja) 2021-05-20 2022-05-19 リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用

Country Status (9)

Country Link
EP (1) EP4340861A4 (https=)
JP (1) JP2024519917A (https=)
KR (1) KR20240040681A (https=)
CN (1) CN117750966A (https=)
AU (1) AU2022279235A1 (https=)
BR (1) BR112023024170A2 (https=)
CA (1) CA3176718A1 (https=)
IL (1) IL308481A (https=)
MX (1) MX2023013744A (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
EP3094327A1 (en) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

Similar Documents

Publication Publication Date Title
US20220168255A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
TWI468191B (zh) 有機化合物之調配物
EP2205279B1 (en) Pharmaceutical combination of aliskiren and valsartan
HUP0204409A2 (en) Sustained release ranolazine pharmaceutical compositions
CN101132777A (zh) 用于睡眠障碍的药物组合物
HUP0104088A2 (hu) Késleltetett felszabadulású ranolazinkészítmények alkalmazása
JP2007509155A5 (https=)
US20030147957A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
JP2019529570A (ja) ミドドリンの組成物およびその使用方法
JP5362556B2 (ja) アリスキレンおよびヒドロクロロチアジドのガレヌス製剤
US20110123612A1 (en) Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
CN114096530B (zh) 一种复合物的药物组合物及其制备方法
JP2024519917A5 (https=)
CN101496792A (zh) 普萘洛尔或其盐的迟释制剂及其制备方法
US20110195117A1 (en) Controlled release compositions of ropinirole
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
HK1161125B (en) Galenic formulations comprising aliskiren